Weill Cornell, New York Presbyterian launch Institute for Precision Medicine
Will put 'advanced technology' to work in finding personalized curesNEW YORK | January 31, 2013
Weill Cornell and NewYork-Presbyterian will invest in "state-of-the-art" technology to conduct sequencing, a more expansive biobank for all patient specimens and tissue samples and dedicated bioinformaticians who will closely analyze patient data, searching for genetic mutations and other abnormalities to identify and target with treatment, officials say.
"The Institute for Precision Medicine will enable our doctors to tailor effective treatments for individual patients and also predict the diseases that are likely to affect a patient long before they develop," says Steven J. Corwin, MD, CEO of NewYork-Presbyterian Hospital. "By harnessing the full potential of our enhanced understanding of the human genome, and extending its reach into the clinical realm, the institute will transform patient care at NewYork-Presbyterian/Weill Cornell Medical Center and beyond."